Among patients with stage III and IV HNSCC, the 5-year DFS rate in the group of patients with TACR1 methylation was 31.4%, as compared with 56.7% in the group with nonmethylated TAC1 [74]. This evidence concerns the gene TAC1 and head and neck squamous cell carcinoma.